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Abstract In mice, vaccination with high peptide doses
generates higher frequencies of specific CD8? T cells, but
with lower avidity compared to vaccination with lower
peptide doses. To investigate the impact of peptide dose on
CD8? T cell responses in humans, melanoma patients
were vaccinated with 0.1 or 0.5 mg Melan-A/MART-1
peptide, mixed with CpG 7909 and Incomplete Freund’s
adjuvant. Neither the kinetics nor the amplitude of the
Melan-A-specific CD8? T cell responses differed between
the two vaccination groups. Also, CD8? T cell differen-
tiation and cytokine production ex vivo were similar in the
two groups. Interestingly, after low peptide dose vaccina-
tion, Melan-A-specific CD8? T cells showed enhanced
degranulation upon peptide stimulation, as assessed by
CD107a upregulation and perforin release ex vivo. In
accordance, CD8? T cell clones derived from low peptide
dose-vaccinated patients showed significantly increased
degranulation and stronger cytotoxicity. In parallel, Melan-
A-specific CD8? T cells and clones from low peptide
dose-vaccinated patients expressed lower CD8 levels,
despite similar or even stronger binding to tetramers.
Furthermore, CD8? T cell clones from low peptide dose-
vaccinated patients bound CD8 binding-deficient tetramers
more efficiently, suggesting that they may express higher
affinity TCRs. We conclude that low peptide dose vacci-
nation generated CD8? T cell responses with stronger
cytotoxicity and lower CD8 dependence.
Keywords Human CD8? T cells  Peptide dose for
vaccination  Tumor-antigen Melan-A/MART-1 
Melanoma
Introduction
CTL responses specific for tumor-associated antigens can
be expanded in melanoma patients by peptide vaccination
[1–4]. However, for protection against cancer and infec-
tion, sufficient frequencies of specific CTL are necessary
[5, 6], as well as additional qualitative features of generated
CTL responses. In general, high-avidity CTL are more
efficient at target cell lysis than their low-avidity counter-
parts [7–12], and their presence is correlated with superior
virus control in mice [7, 8, 10, 13], macaques [14] and
humans [15, 16], and tumor rejection in a mouse model
[11]. Furthermore, the presence of polyfunctional CTL has
been shown to correlate with enhanced viral [15, 17] and
tumor [5, 18] control. Thus, when evaluating CTL
responses, it is important to consider not only frequencies
but also avidity and functionality of induced CTL.
The characteristics of CTL responses are affected by the
nature of the stimuli (e.g., antigen, immune modulators),
the anatomical site and the timing of stimulation [19, 20].
During vaccine-induced responses, CTL characteristics
depend on vaccination route/schedule and vaccine com-
ponents (e.g., antigens, adjuvants) and their doses [4].
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Regarding dosing, increased peptide doses were shown to
induce higher numbers of specific CD8? T cells in mice
[21–24]. However, in many cases, these cells included
increased proportions of low-avidity cells as compared to
lower peptide dose vaccination [8, 21, 24]. This may be
explained by recruitment of low-avidity precursors, dele-
tion of high-avidity cells, and/or CD8 downregulation
induced by high peptide dose vaccination [8].
In humans, the effect of peptide dosing on specific CTL
frequencies is less well established. Positive correlation
between frequencies of specific CTL and administered
peptide doses have been reported, mainly comparing very
low doses (5–50 lg/vaccine) with higher doses [25, 26],
but many studies on vaccination with peptide, including
Melan-A peptide [2], showed no effect on frequencies of
specific cells by increasing peptide doses [27, 28]. Proba-
bly, the lowest administered doses already induced the
highest specific CTL frequencies possible with the
respective vaccination approach. Such a plateau in the
generated response was shown in two large randomized,
double-blinded and placebo-controlled studies on the HCV
multipeptide vaccine IC40 where lower frequencies of
specific CTL were found with the lowest used dose
(0.5 mg) [29], while no differences were seen between
intermediate (2.5 mg) and high (5 mg) peptide doses [28,
29]. However, it is also possible that technical limitations
of T cell analysis overlooked true differences in T cell
responses. For example, T cell frequencies were often
determined after in vitro expansion for one or more weeks
without limiting dilution techniques, precluding precise
evaluation. Moreover, biological samples were taken at a
single time point after vaccination, differing between
studies, and time kinetics were not analyzed. Furthermore,
qualitative CTL data for CTL function and avidity/affinity
for antigen recognition are lacking.
Here, we analyzed CTLs from melanoma patients after
vaccination with two different doses of Melan-A peptide.
Vaccination with this peptide, together with CpG oligo-
nucleotide (ODN) and IFA, generates strong CTL respon-
ses [3], allowing multiparameter functional analysis
directly ex vivo using pMHC tetramers. Furthermore, we
generated CD8? T cell clones, representative for in vivo
TCR repertoires [30, 31], and determined functional avid-
ity and lytic capacity. Data demonstrate that the lower
peptide dose induced qualitatively superior CTL.
Materials and methods
Patients and blood samples
HLA-A*0201-positive patients with stage III–IV mela-
noma received monthly vaccinations s.c. with Melan-A/
MART-126–35 A27L analog peptide (ELAGIGILTV), at
0.1 mg (low dose, 10 male and 6 female patients) or
0.5 mg (high dose, 3 male and 2 female patients). Vaccine
emulsions were prepared with incomplete Freund’s adju-
vant (IFA, Montanide ISA-51; Seppic), CpG ODN (CpG
7909/PF-3512676; Pfizer) and peptide as described else-
where [3]. Clinical procedures were approved by the LICR
protocol review committee and the ethical committee of
the University Hospital of Lausanne. Peripheral blood
mononuclear cells (PBMC) were prepared from peripheral
blood, by Ficoll-Hypaque (GE Healthcare) density centri-
fugation, and frozen in liquid nitrogen in 10% dimethyl
sulphoxide (DMSO; Gibco) and 50% FCS (Gibco) in
RPMI 1640 (Gibco). Standard differential blood counts
were determined, to allow calculating absolute lymphocyte
numbers, based on percentages identified by flow
cytometry.
Flow cytometry, cell sorting and generation
of CD8? T cell clones
Unless otherwise stated, stainings were performed with
saturating concentrations of monoclonal antibodies from
BD Biosciences, at 4C for 20 min, in PBS containing
0.2% BSA and 2 mM EDTA for ex vivo samples and
sortings, and in PBS containing 0.2% BSA, 5 mM EDTA
and 0.2% sodium azide for clones. Melan-A-specific
CD8? T cells were stained at 4C for 45 min with satu-
rating amounts of PE-labeled HLA-A*0201/Melan-A26–35
analog A27L peptide tetramers [32, 33]. In addition,
D227K/T228A-mutated tetramers unable to interact with
CD8 (CD8-null tetramers [34, 35]) were used. A FACS-
Vantage SE (BD Bioscience) was used for monitoring and
sorting and a GalliosTM (Beckman Coulter) for other flow
cytometry. CD8? T cells were enriched from PBMC using
CD8 microbeads (Miltenyi Biotech). Since we noted
inability of IL-2 production immediately after thawing, for
cytokine assessments, PBMC were incubated over night at
37C, 5% CO2 in 8% human serum-containing medium
without IL-2 prior to CD8 enrichment.
For monitoring and sorting, tetramer-stained CD8
enriched T cells were stained with CD8-APC-Cy7, CD45
RA-ECD (Beckmann-Coulter), CD28-FITC and purified
rat-anti-human CCR7 followed by goat-anti-rat immuno-
globulin-APC. Cloning was performed upon sorting of
Melan-A-specific CD8? CD45RA- CCR7- (effector
memory; EM) cells. Cells (0.5 cells/well) were cultured in
Terasaki plates (Nunc), stimulated with 1 lg/ml phytohe-
magglutin (PHA HA16; Murex Biotech) and 0.5 9 106/ml
irradiated (30 Gy) PBMC. Clones were kept at 37C, 5%
CO2 in 8% human serum-containing RPMI 1640 supple-
mented with 150 U/ml human IL-2 (Roche Applied Sci-
ence) and were restimulated every 2–3 weeks. T cell clones
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were generated from blood drawn after four vaccinations,
and at a few occasions from earlier and later time points
(2–12 vaccines). Experiments were performed between day
11 and 15 after the previous restimulation, with maximally
three restimulations.
For degranulation and cytokine assessment, 200,000–
480,000 tetramer-stained CD8? T cells or 400,000 clone
cells were added to 96-well flat-bottom plates, in 0.1 ml
10% FCS RPMI 1640 with CD107a-PE-Cy5 and 200,000
T2 cells, alone or pre-pulsed with 10 lM Melan-A peptide
at 37C, 1 h. After 4 h at 37C, 5% CO2, cells were har-
vested and stained with CD8-APC-H7 (ex vivo experi-
ments) or CD8-Pacific blue (clones), and abTCR-PE.
Staining with Live/Dead fixable aqua stain (InVitrogen),
diluted in PBS, was performed at 4C for 30 min with pure
PBS washes before and after. Cells were fixed with 1%
paraformaldehyde, 2% glucose and 5 mM sodium azide in
PBS at 4C over night before intracellular staining in 0.1%
saponin (Sigma) with TNF-a-Alexa700, IFN-c-PE-Cy7 and
rat-anti-human IL2-APC and, in ex vivo samples also
Granzyme B-ECD and Perforin-FITC. In clones, perforin
and granzyme B expression was assessed separately by
staining with CD8-APC-H7, Live/Dead fixable aqua, fix-
ation, and intracellular Granzyme B-ECD and Perforin-
FITC.
Chromium release assays
Clones were examined for lytic capacity with 51Cr labeled
T2 (HLA-A*0201?/Melan-A-) or C1R cells, the latter
transfected with wild type or D227K/T228A mutated HLA-
A*0201. Duplicate wells with 10,000 effector cells, 1,000
target cells and Melan-A peptide titrated in tenfold dilu-
tions from 1 9 10-6 M to 1 9 10-12 M or unspecific
peptide (influenza matrix protein58–66 peptide; GIL-
GFVFTL) were used. Tumor cell recognition was mea-
sured in duplicates of 30,000, 10,000, 3,000 or 1,000 clone
cells and 1,000 51Cr labeled HLA-A*0201?/Melan-A?
Me290 or HLA-A*0201?/Melan-A- Na8 melanoma cell
lines with or without 1 9 10-6 M Melan-A peptide.
Spontaneous lysis in target cells alone and maximum lysis
with 1 M HCl addition was measured. After 4 h at 37C,
5% CO2, supernatants were transferred to LumaPlate
TM
96-well plates (PerkinElmer) and measured with a Top
Count NXT plate reader (PerkinElmer).
Detection of mRNA for Fas ligand, granzyme B
and perforin
Lysis and cDNA synthesis from 10,000 cells per reaction were
performed in one step before PCR [36]. Fas ligand (Forward:
50-GGGCCCCTCCAGGCACAGTT-30, Reverse: 50-CTGCT
GCGGGCCCACATCTG-30), Granzyme B (Forward: 50-AG
ATGCAACCAATCCTGCTT-30, Reverse: 50-TCTGGG
TCCCCCACGCACA-30), perforin (Forward: 50-GGCTGG
TGCAAGGAGCCACA-30, Reverse: 50-GCGGATGCTAC
GAGCCGCAT-30) and CD3 (Forward: 50-GCGGCAGGC
AAAGGGGACAA-30, Reverse: 50-GCCAGCGGGAGGCA
GTGTTC-30) specific primers were used and a program of 5
initial minutes at 95C, thereafter 30 cycles of 30 s at 95C,
30 s at 63C and 30 s at 72C, and finally 72C for 1 min, on a
T1 Thermocycler (Biometra). The cDNA quality was assured
by CD3 mRNA detection.
Data analysis and statistics
Comparison between groups was performed with unpaired
t test or, where mentioned, Fisher’s exact test. Flow cytometry
data were analyzed with FlowJo 7.6 (TreeStar) employing a
gating strategy with a live lymphocyte gate in forward (FSC-
A) and side-scatter (SSC-A), doublet-exclusion (FSC-A/FSC-
H and SSC-A/SSC-H) and dead cell-exclusion with a dead cell
marker. Quadrant/gate percentages or geometrical mean MFI
values were exported and, for CD107a and cytokines, mock
background MFI was subtracted. Release of perforin was
calculated as (%perforin? cells in mock - %perforin? cells
in T2_peptide stimulated samples)/%perforin? cells in
mock. Absolute numbers of specific cells per liter of blood
were calculated as (leukocyte count/liter of blood) 9 %lym-
phocytes 9 %CD8? cells 9 %Melan-A tetramer? cells.
Specific lysis in percentage was calculated as 100 9 (exper-
imental release - spontaneous release)/(total release -
spontaneous release), and half maximal effective concentra-
tion (EC50) was calculated by GraphPad Prism 5 (GraphPad
Software) and the ‘‘log (agonist) versus response (three
parameters)’’ sigmoid model. In tumor cell recognition
experiments, lytic units (LU) within 1 9 107 T effector cells
were calculated, with one lytic unit being defined as the
number of effector cells needed for 30% specific lysis. Out-
liers where the range of tested effector to target ratios did not
encompass the 30% target cell lysis were set as \333 or
[10,000 L.U. per 107 which prevents direct statistical com-
parison [37].
Results
Similar frequency, differentiation and cytokine
production of Melan-A-specific CD8? T cells
after vaccination with low and high peptide doses
Patients received monthly vaccinations s.c. with different
doses of Melan-A peptide, i.e., 0.1 mg (‘‘low dose’’) or
0.5 mg (‘‘high dose’’), supplemented with CpG ODN and
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IFA. Flow cytometric monitoring was performed at several
time points after vaccination to determine frequencies and
differentiation status of Melan-A-specific CD8? T cells
(Fig. 1a–e, Suppl Fig 1a and b). Comparing low versus
high peptide dose-vaccinated patients, we found no sig-
nificant differences in maximally reached Melan-A-specific
CD8? T cell frequencies (Fig. 1b, Suppl Fig 1a), and no
difference in the number of vaccinations needed to reach
this maximum response (Fig. 1c). As previously reported
[3], most of the specific cells were CD45RA- CCR7-
effector memory (EM) cells, and smaller proportions
CD45RA? CCR7- effector (EMRA) cells, while very few
were of CD45RA? CCR7? naı¨ve or CD45RA- CCR7?
central memory (CM) phenotype (Fig. 1d). Finally, sub-
stantial proportions of the EM and smaller proportions of
the EMRA lacked CD28 expression (Fig. 1e), a feature
associated with enhanced effector differentiation [38, 39].
Thus, vaccinations were efficient, without apparent impact
of the peptide dose on T cell differentiation.
To analyze T cell function, blood-derived CD8? T cells
obtained after 4 or 5 monthly vaccinations were labeled
with Melan-A tetramers, stimulated with peptide-pulsed T2
cells for 4 h and stained intracellularly for TNF-a and IL-2
(Fig. 2a). Due to technical limitations, we could not
simultaneously include extended phenotyping, which was
however not a major limitation since most specific cells
were known to be EM and EMRA cells (Fig. 1d). We
found that there were no significant differences between
vaccination groups in percentages of TNF-a (Fig. 2b) and
IL-2 (Fig. 2c) positive cells, or amounts of each cytokine
produced per cell (measured as MFI; results not shown).
Increased target cell lysis due to enhanced
degranulation by Melan-A-specific CD8? T cells
from low peptide dose-vaccinated patients
For more detailed analysis of T cell function, Melan-A-
specific CD8? T cell clones were generated from PBMC
of the two patients groups, by sorting Melan-A tetramer?
EM cells (Suppl Fig 1b). In accordance with ex vivo
findings, clones from the two vaccination groups produced
similar levels of IL-2 and TNF-a upon 4 h peptide stimu-
lation (results not shown). However, cytotoxicity assays
revealed that clones derived from low peptide dose-vacci-
nated patients lysed Melan-A peptide-pulsed target cells
significantly better than clones from high dose-vaccinated
patients (Fig. 3a). In fact, clones from each low peptide
dose-vaccinated patient had a mean maximal lysis that was
higher than each one of the high peptide dose-vaccinated
patients (Suppl Fig 2b). To further investigate importance
of differences in lytic capacity, we measured lysis of the
naturally Melan-A-expressing melanoma cell line Me290,
and the Melan-A negative melanoma cell line Na8. We
calculated specific lysis (Suppl Fig 2c) and lytic units per
1 9 107 effector cells (Fig. 3b). We found a trend toward
stronger lysis of Me290 cells by CD8? T cell clones from
low peptide dose-vaccinated patients, which was also
found after adding saturating amounts (1 lM) of peptide.
As expected, Na8 cells were poorly lysed in absence of
synthetic peptide, but after addition of 1 lM Melan-A
peptide, clones from the low peptide dose-vaccinated group
lysed Na8 cells better than clones from the high peptide
dose group.
To determine the cause of decreased cytotoxicity in
clones from high peptide dose-vaccinated patients, we
assessed the capacity of degranulation. This was done by 4 h
stimulation with peptide-pulsed T2 cells and cell-surface
Fig. 1 Similar frequencies and differentiation of Melan-A-specific
CD8? T cells after vaccination with low and high peptide doses.
Percentages of circulating Melan-A-specific cells in CD8? T cells
after vaccination with 0.1 mg peptide (low dose; n = 16 patients) and
0.5 mg peptide (high dose; n = 5) determined directly ex vivo by
flow cytometry. Shown are a representative dot plot of ex vivo Melan-
A-specific CD8? T cells in patient blood after four vaccinations (a),
percentages of Melan-A-specific T cells at time of peak response (b),
the number of vaccinations needed to reach this peak (c) and the
differentiation status of the specific CD8? T cells, determined as
fraction of naı¨ve (CCR7? CD45RA?), central memory (CM;
CCR7? CD45RA-), effector memory (EM; CCR7-, CD45RA-)
and effector RA? (EMRA; CCR7-, CD45RA?) cells within Melan-
A-specific CD8? T cells (d) and fraction of CD28-cells (e) in Melan-
A-specific EM or EMRA subpopulations. Data points for each patient
and mean ± SEM are shown. N.S. not significant
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staining for CD107a/LAMP-1 (Fig. 3c), an endosome
marker appearing on the cell-surface upon degranulation
[40]. In Melan-A-specific CD8? T cells analyzed ex vivo,
we observed a trend toward higher cell-surface expression
of CD107a on cells from low peptide dose-vaccinated
patients, when measured as fraction of CD107a-positive
cells (Fig. 3d), or as level of expression on individual cells
(Fig. 3e). Consistent with these findings, CD107a expres-
sion was significantly higher on clones from the low peptide
dose-vaccinated group (Fig. 3f, Suppl Fig 1e).
In contrast to CD107a, the percentages of perforin and
granzyme B positive Melan-A-specific CD8? T cells were
slightly lower after low peptide dose vaccination (Fig. 4a,
b and Suppl Fig 1c). In parallel, we also found slightly
reduced mean fluorescence intensities of staining for per-
forin and granzyme B (Fig. 4d, e). However, percentages
of Melan-A-specific CD8? T cells that lost their perforin
content after stimulation with peptide-loaded T2 cells were
significantly higher in the low peptide dose-vaccinated
group (Fig. 4c, Suppl Fig 1c). This is consistent with
stronger degranulation, resulting in reduced amounts of
intracellular perforin [40]. In contrast to perforin, gran-
zyme B expression was not reduced (results not shown),
probably due to rapid de novo synthesis of mature gran-
zyme B, whereas perforin is synthesized as an inactive
precursor not recognized by the antibody used [41]. In
clones generated from the two patient groups, the perforin
and granzyme B levels were similar, on the protein
(Fig. 4f, g and Suppl Fig 1d) and also on the mRNA level
(Table 1). We also analyzed mRNA expression of Fas
ligand (CD178) that induces cytotoxicity via ligation with
Fas (CD95) death receptor on target cells. Fas ligand was
detected in very few clones, almost exclusively from the
high peptide dose vaccination group (Table 1).
Reduced CD8 dependence of Melan-A-specific CD8?
T cells from low peptide dose-vaccinated patients
A central parameter for T cell functional competence is
avidity for cognate antigen expressing target cells. To
determine the ‘‘functional avidity’’ of cells generated after
vaccination with the two different peptide doses, cytotoxic
assays were performed with graded concentrations of
peptide used for T2 target cell labeling, and peptide con-
centration required for half maximal lysis EC50 was
determined. We found no difference in functional avidity
between Melan-A-specific clones from the two patient
groups (Fig. 5a). Most clones had functional avidities (i.e.
EC50) in the range of 1 9 10-12 to 1 9 10-9 M. In
addition, clones with EC50-values of[1 9 10-10 M were
Fig. 2 Equal capacity of
cytokine production by Melan-
A-specific CD8? T cells from
patients vaccinated with low
and high doses of Melan-A
peptide. CD8? T cells from low
(n = 6) and high (n = 5) dose-
vaccinated patients were
analyzed directly ex vivo, upon
triggering with unpulsed or
Melan-A peptide-pulsed T2
cells for 4 h, followed by
intracellular staining for TNF-a
(a, b) and IL-2 (a, c). Dot plots
of Melan-A-specific CD8? T
cells are shown from two
representative patients (a) and
percentages of cytokine positive
cells for each patient, with
mean ± SEM (b, c)
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Fig. 3 Superior capacity of degranulation and target cell lysis by
Melan-A-specific CD8? T cells from low peptide dose-vaccinated
patients. Melan-A-specific CD8? clones were assessed for ability to
lyse Melan-A peptide-pulsed T2 target cells (a, n = 323 for low,
n = 94 for high peptide dose) or melanoma cell lines (b, n = 14 for
low, n = 15 for high peptide dose) positive (Me290) or negative
(Na8) for Melan-A expression, with (?ELA) and without additional
peptide. Percent specific lysis (a) or lytic units within 107 effector
cells (b) are shown as individual data points for each clone, and
mean ± SEM for the two patient groups. Ability of ex vivo Melan-A-
specific CD8? T cells (c–e, n = 6 for low, n = 5 for high peptide
dose) or clones (f, n = 22 for low, n = 17 for high peptide dose) to
degranulate was measured as surface expression of CD107a during
peptide stimulation. Shown are representative histograms for CD107a
expression by Melan-A-specific CD8? T cells analyzed ex vivo (c),
after stimulation with T2 cells without or with Melan-A peptide.
Percentages of positive cells (d) or expression per cell (e, mean
MFI ± SEM) by ex vivo Melan-A-specific CD8? T cells, or by
Melan-A-specific clones (f, mean MFI ± SEM) for each specified
group are depicted
Fig. 4 Similar steady-state expression of perforin/granzyme B, but
increased capacity of perforin release by Melan-A-specific CD8? T
cells from patients vaccinated with low peptide dose. Intracellular
staining of perforin (a, c, d) and granzyme B (b, e) was performed in
ex vivo Melan-A-specific CD8? T cells (a–e, n = 6 for low, n = 5
for high peptide dose) or Melan-A-specific CTL clones (f, g) from
vaccinated patients. Depicted are percentages of perforin (a) or
granzyme B (b) positive Melan-A-specific CD8? T cells for the two
patient groups, or percentages of specific cells that lost intracellular
expression of perforin upon 4 h stimulation with peptide-loaded target
cells (c). Results are shown per patient/clone as well as mean ± SEM.
Also shown are mean MFI ± SEM for specific cells (d, e) or clones
(f, g; n = 43 for low, n = 20 for high peptide dose)
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found in almost all patients and were not more common in
the high peptide dose-vaccinated group (Suppl Fig 2a).
Two major factors influencing avidity are the capacity of
the T cell to bind peptide/MHC complexes via the TCR and
via CD8. We analyzed tetramer binding, as well as CD8
expression levels in Melan-A-specific cells. We found a
trend to weaker tetramer staining (Fig. 5b) and higher CD8
expression (Fig. 5c) in Melan-A peptide-specific cells from
patients vaccinated with the high peptide dose.
On clones, staining with wild-type Melan-A tetramer
was similar in the two vaccination groups (Fig. 5e).
However, using mutated HLA-A*0201 (D227K/T228A)
tetramers that are unable to bind CD8 (‘‘CD8-null tetra-
mers’’), clones from high peptide dose-vaccinated patients
showed significantly lower staining (Fig. 5d). Furthermore,
CD8 expression levels were significantly higher on clones
from high peptide dose-vaccinated patients (Fig. 5f).
Higher CD8 expression and stronger CD8 dependence of
Melan-A-specific T cells from high peptide dose-vacci-
nated patients suggest that these T cells compensate lower
affinity TCRs with enhanced CD8 function.
Discussion
In this study, we investigated whether the dose of peptide
used for vaccination affected frequency, functionality,
cellular composition or avidity of the responding CD8? T
cells. As reported previously, vaccination with Melan-A
peptide, CpG and IFA induced high levels (up to 8%) of
specific CTL, well detectable ex vivo [3]. This is in con-
trast to many other cancer vaccination studies that required
one or several weeks of in vitro T cell expansion to reach
detectable levels of antigen-specific T cells.
Vaccination with high doses of antigen in mice has
shown to result in increased CD8? T cell frequencies [21–
24]. In melanoma patients, up to 38% of antigen-specific
CD8? T cells were reported to be induced by vaccination
with gp100 peptide and IFA [42]. This was achieved with
high doses of peptide (1 mg) per injection, and frequent
(weekly) booster vaccinations (up to 40 vaccinations),
resulting in high cumulative peptide doses (20- to 100-fold
higher than in our study). It remains to be determined
which of these parameters are more important for T cell
quantity and quality, respectively. In our study, similar to
most other studies in humans, there were no marked dif-
ferences in frequencies of tumor-specific T cells generated
with different doses of peptide [2, 27, 28]. Conversely, in
terms of T cell function, we observed enhanced degranu-
lation upon peptide triggering in CD8? T cells from low
peptide dose-vaccinated patients, revealing increased
functionality. In accordance, we found significantly
increased degranulation in CD8? T cell clones from low
peptide dose-vaccinated patients. Consequently, ability of
clones from low peptide dose-vaccinated patients to lyse
peptide-pulsed target cells was significantly increased.
Similarly, the ability to lyse melanoma cells naturally
expressing Melan-A was more efficient, indicating that low
Table 1 mRNA expression for effector molecules in CD8? T cell
clones
Detected mRNA Clones
0.1 mg 0.5 mg P value
Fas ligand 5.6a 26 P \ 0.05b
Perforin 8.3 21 N.S.
Granzyme B 50 47 N.S.
N.S. not significant
a Percentages of clones with detectable levels of Fas ligand, perforin
or granzyme B mRNA
b Significance was calculated with Fisher’s exact test
Fig. 5 Decreased CD8 dependence but similar avidity of Melan-A-
specific CD8? T cells from low peptide dose-vaccinated patients.
Functional avidity of Melan-A-specific clones was determined as
logEC50 (M) of Melan-A peptide (a). Values are depicted as separate
data points and mean ± SEM for the specified group (low peptide
dose: n = 247, high peptide dose: n = 60). Ex vivo CD8? T cells
(b, c; n = 6 for low, n = 5 for high peptide dose) or Melan-A-
specific CD8? T cell clones (d–f; CD8: n = 43 for low, n = 20 for
high peptide dose, tetramers: n = 29 for low, n = 20 for high peptide
dose) from vaccinated patients were stained with wild-type Melan-A
tetramers (b, e) or for CD8 (c, f). Clones were also stained with
mutated Melan-A tetramer unable to bind CD8 (d). Mean MFI ±
SEM is depicted for clones from each specified group
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peptide dose vaccination selectively promoted degranula-
tion and thereby cytotoxic capacity of specific T cells.
We found no differences in proportions of CD8? T cell
subsets (naı¨ve, CM, EM, EMRA cells), positive or negative
for CD28 expression. Also, the expression of perforin and
granzyme B was similar. Therefore, increased cytotoxicity
of CD8? T cells after low peptide dose vaccination was
due to enhanced TCR triggering, and/or improved signal-
ing leading to more efficient lytic granule release.
Vaccination of mice with higher peptide doses has been
reported to result in lower avidity T cells [8, 21, 24]. We
found no difference in functional avidity in clones from low
or high peptide dose-vaccinated patients. However, binding
to peptide/MHC was stronger, and CD8 expression was
lower after low peptide dose vaccination. Since CD8 con-
tributes to tetramer binding [34], our findings suggest higher
TCR affinity that is counter-acted by lower CD8 expression
after low peptide dose vaccination. This is confirmed by the
finding of significantly stronger CD8-null tetramer staining
of T cell clones from low peptide dose-vaccinated patients.
We also investigated the impact of the decreased CD8
dependency in Melan-A-specific CD8? T cells from low
peptide dose-vaccinated patients, by performing lysis assays
with target cells expressing CD8-null MHC. However, due
to low cytotoxicity in absence of CD8 involvement, we were
unable to determine their functional avidity and could
therefore not formally demonstrate binding differences. Our
data support the notion that T cells with higher functional
avidity still require CD8 for efficient interaction with target
cells, despite that they may be less CD8 dependent. Toge-
ther, our findings are compatible with the well-known ability
of T cells to modulate their avidity by constant tuning of
CD8 expression [43–46], which appears to be a fundamental
mechanism for the adaption of T cell avidity as part of the
complex regulation of immune responses.
Our findings are remarkable in the sense that they show
that even small changes in peptide dose (i.e., fivefold) can
affect the quality of the generated CD8? T cell response in
vivo to a small but nevertheless significant degree. Fur-
thermore, they highlight the importance of not only mea-
suring frequencies of specific T cells, but also investigating
their functionality. There were no obvious differences in
progression free survival and overall survival between
patients vaccinated with low versus high peptide dose
(results not shown). However, this study was not designed
for statistical analysis of clinical outcome, which would
require larger patient numbers.
Our data provide a rationale for future vaccination trials,
using carefully selected antigens and adjuvants eliciting T
cell responses with multiple tumor-antigen specificities,
whereby low antigen doses may promote strong T cell
responses. Very low peptide doses, at least for initial
vaccinations, have been suggested to result in higher
fractions of high-avidity cells [47]. In our study, the lower
peptide dose resulted in activation of T cells with improved
degranulation and cytotoxic capacity and reduced CD8
dependence.
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